Metagenomi, Inc. Common Stock (MGX)
USD 3.11
(-8.26%)
USD 3.11
(-8.26%)
| Breakdown | 2023 | 2022 | 2021 |
|---|---|---|---|
| Revenue | 44.75 Million | 17.2 Million | 243 Thousand |
| Cost of Revenue | 94.4 Million | 1.73 Million | 387 Thousand |
| Gross Profit | -49.64 Million | 15.46 Million | -144 Thousand |
| Operating Expenses | 28.84 Million | 61.84 Million | 24.19 Million |
| Selling, General and Administrative Expenses | 28.84 Million | 18.7 Million | 9.71 Million |
| Research and Development Expenses | 94.4 Million | 43.13 Million | 14.47 Million |
| Other Expenses | - | 201 Thousand | 4000.00 |
| Cost and Expenses | 123.24 Million | 61.84 Million | 24.19 Million |
| Operating Income | -78.49 Million | -44.64 Million | -23.94 Million |
| Interest Expense | - | 98 Thousand | 302 Thousand |
| Income Tax Expense | 8.02 Million | 2.56 Million | 306 Thousand |
| Earnings before Tax | -60.22 Million | -41.02 Million | -21.44 Million |
| Net Income | -68.25 Million | -43.59 Million | -21.44 Million |
| Earnings Per Share Basic | -1.82 | -1.45 | -0.72 |
| Earnings Per Share Diluted | -1.82 | -1.45 | -0.72 |
| Weighted Average Shares Outstanding | 37.52 Million | 29.96 Million | 29.96 Million |
| Weighted Average Shares Outstanding (Diluted) | 37.52 Million | 29.96 Million | 29.96 Million |
| Gross Margin | -1.11 | 0.90 | -0.59 |
| EBIT Margin | -1.25 | -2.28 | -96.76 |
| Profit Margin | -1.53 | -2.53 | -88.24 |
| EBITDA | -56.02 Million | -39.19 Million | -20.75 Million |
| Earnings Before Tax Margin | -1.75 | -2.60 | -98.55 |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Revenue | 20 Million | 11.15 Million | 12.39 Million | 44.75 Million | 12.36 Million | 11.33 Million |
| Cost of Revenue | 1.3 Million | 1.27 Million | 1.2 Million | 4.2 Million | 1.15 Million | 1.01 Million |
| Gross Profit | 18.69 Million | 9.88 Million | 11.19 Million | 40.54 Million | 11.2 Million | 10.32 Million |
| Operating Expenses | 35.56 Million | 40.19 Million | 32.59 Million | 123.24 Million | 34.75 Million | 29.3 Million |
| Selling, General and Administrative Expenses | 7.24 Million | 8.75 Million | 7.84 Million | - | 7.92 Million | 6.61 Million |
| Research and Development Expenses | 28.32 Million | 31.43 Million | 24.75 Million | - | 26.83 Million | 22.68 Million |
| Other Expenses | -51 Thousand | -50 Thousand | -4000.00 | -74 Thousand | -85 Thousand | 16 Thousand |
| Cost and Expenses | 36.87 Million | 40.19 Million | 32.59 Million | 123.24 Million | 34.75 Million | 29.3 Million |
| Operating Income | -16.86 Million | -29.03 Million | -20.19 Million | -78.49 Million | -22.39 Million | -17.96 Million |
| Interest Expense | - | - | - | - | - | - |
| Income Tax Expense | -2.19 Million | -3.93 Million | 2.72 Million | 8.02 Million | 1.2 Million | 1.89 Million |
| Earnings before Tax | -12.93 Million | -25.14 Million | -16.56 Million | -60.22 Million | -18.61 Million | -11.11 Million |
| Net Income | -10.73 Million | -25.14 Million | -19.29 Million | -68.25 Million | -19.82 Million | -13 Million |
| Earnings Per Share Basic | -0.29 | -1.19 | -0.51 | - | -0.53 | -0.39 |
| Earnings Per Share Diluted | -0.29 | -1.19 | -0.51 | - | -0.53 | -0.39 |
| Weighted Average Shares Outstanding | 37.45 Million | 21.13 Million | 37.47 Million | 37.52 Million | 37.47 Million | 33.71 Million |
| Weighted Average Shares Outstanding (Diluted) | 37.45 Million | 21.13 Million | 37.47 Million | 37.52 Million | 37.47 Million | 33.71 Million |
| Gross Margin | 0.93 | 0.89 | 0.90 | 0.91 | 0.91 | 0.91 |
| EBIT Margin | -0.78 | -2.49 | -1.24 | - | -1.41 | -0.54 |
| Profit Margin | -0.54 | -2.25 | -1.56 | -1.53 | -1.60 | -1.15 |
| EBITDA | -15.55 Million | -27.75 Million | -15.36 Million | - | -17.46 Million | -6.09 Million |
| Earnings Before Tax Margin | -0.84 | -2.60 | -1.63 | -1.75 | -1.81 | -1.58 |
9405
IVCGF
DALBHARAT
BOL
HTNGF
4588